PYC Therapeutics is a clinical-stage biotech company that creates therapies for rare genetic diseases. Our purpose is to change lives.
7.09亿总市值-15833市盈率(静) 1.550最高价1.470最低价8.13万股成交量1.470今开1.460昨收12.35万成交额2.10052周最高0.03%换手率4.67亿总股本0.73052周最低-0.096每股收益TTM3.59亿流通值8.600历史最高亏损市盈率(静)2.36亿流通股0.100历史最低-0.096每股收益(静)5.48%振幅--股息TTM8.79市净率1股每手--股息率TTM ...
PYC Therapeutics在2025年初进入首个人体试验时,达到了52周高点,作为肾病药物候选者。 PYC Therapeutics(ASX:PYC)在周三创下52周新高,此前该公司宣布将在2025年初进入针对肾病药物候选物PYC-003的首次人体试验。 MT Newswires11/27 11:05 PYC Therapeutics表示安全审查委员会批准眼疾病研究中将剂量逐步增加至最终患者组...
Hang Seng20,066.19365.631.86% Shanghai3,252.6322.460.70% Sensex76,190.46-329.92-0.43% Singapore3,804.26-2.31-0.06% Latest NewsAll Times Eastern scroll upscroll down Search Ticker | PYCAustralia: Sydney +Watchlist You must be logged in to create alerts ...
Asia FX Rates Futures Crypto RangeDropdown Markets Asia Dow4,295.7671.841.70% Nikkei 22539,149.43-312.04-0.79% Hang Seng22,620.33805.963.69% Shanghai3,346.7214.240.43% Sensex75,939.21-199.76-0.26% Singapore3,877.50-5.08-0.13% Latest NewsAll Times Eastern ...
ACB News《澳华财经在线》8月21日讯,临床阶段 生物科技 公司PYC Therapeutics (ASX股票代码:PYC)获得澳洲医疗用品管理局(TGA)批准,将在本季度启动新药候选物PYC-001人体试验,旨在研究该药物在治疗罕见且致盲眼病——常染色体显性视神经萎缩(ADOA)的安全性和有效性
PYC Therapeutics, a biotechnology company combining two complementary platform technologies to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, announced two upcoming virtual poster...
/PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients...
澳华财经在线数据库显示,PYCTherapeutics是一家临床阶段生物技术公司,致力于创造新一代RNA疗法,以改变遗传病患者的生活。色素性视网膜炎11型(RP11)是一种影响视网膜的遗传性疾病,其特征是视网膜渐进性退化,视力逐渐丧失,并经常导致失明。 RP11候选药上市申请进程表(图片来源:PYC) ...
PYC Therapeutics的公允价值下行边际是25.1% 相比竞争对手,PYC Therapeutics Ltd的公允价值下行边际 (InvestingPro)基准如何? 我们发现下列公司与PYC Therapeutics Ltd相近,它们都属于相关的行业。我们还考虑了规模、增长和各种财务指标,并将列表缩小到以下范围。 PYC Therapeutics Ltd的公允价值下行边际 (InvestingPro)基准 ...